|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent 10,350,186
What is the scope of US Patent 10,350,186?
US Patent 10,350,186, titled "Methods of modulating immune responses using small molecule inhibitors," primarily covers novel small molecule compounds designed to regulate immune responses. The patent encompasses compositions, methods of synthesis, and methods of using these compounds for therapeutic or research applications.
Key aspects of the scope include:
- Small molecules with specific chemical structures, including particular functional groups.
- Use of these compounds for modulating immune cell activity, including T-cell proliferation and cytokine production.
- Therapeutic applications targeting autoimmune diseases, inflammatory disorders, and transplant rejection.
- Methods of preparing the compounds, including synthesis pathways.
The patent does not claim broad class-based molecules without specific functional group limitations, nor does it cover formulations or delivery methods explicitly.
What are the primary claims of US Patent 10,350,186?
The claims of the patent define the legal boundaries. The core claims are:
Independent Claims:
- Compound Claims: Specific chemical structures, characterized by a core scaffold with variations at particular positions, including substitutions on aromatic rings and linkers, with definitions of the functional groups allowed.
- Use Claims: Methods of modulating immune responses by administering a compound characterized as per claims 1-10.
- Method Claims: Including methods to treat autoimmune diseases, inflammatory disorders, or prevent transplant rejection with the compounds.
Dependent Claims:
- Details on specific chemical substituents (e.g., methyl, halogen).
- Specific dosages, formulations, or combination therapies.
- Synthesis methods tailored for particular compounds.
Claim Summary:
The primary claims focus on compounds with a specified heterocyclic core structure, with various substitutions, and their use in immune modulation.
How broad is the patent landscape for immune-modulating small molecules?
The patent landscape for immune-modulating small molecules is highly active, including:
| Patent Class |
Focus Area |
Approximate Number of Patents |
Notable Stakeholders |
| 424/400 |
Organic compounds as medicaments |
20,000+ |
Pfizer, Novartis |
| 514/909 |
Immunomodulators |
8,000+ |
GSK, AbbVie |
| 514/246 |
Cytokine modulators |
5,000+ |
Merck, Roche |
Trends:
- Increasing filings for small molecules targeting specific immune pathways, including JAK inhibitors, BTK inhibitors, and adenosine receptor antagonists.
- Many patents focus on chemical modifications to improve potency, selectivity, and pharmacokinetics.
- Several filed patents overlap in target indications such as autoimmune diseases and transplant rejection.
Key patent families:
- JAK inhibitors (e.g., tofacitinib, baricitinib)
- BTK inhibitors (e.g., ibrutinib)
- Adenosine receptor antagonists (e.g., CPI-444)
In light of this landscape, the specific chemical features and methods claimed in US 10,350,186 provide a narrower scope relative to broad immunomodulator patents, potentially reducing infringement risks.
What is the patent lifecycle and relevance?
US Patent 10,350,186 was granted in July 2019, with a 20-year term from application date (filing date: September 2014). The expiration is expected around September 2034, assuming maintenance fees are paid.
Relevance:
- The patent protects specific chemical entities and their use, making it significant for companies pursuing similar immune-modulating compounds.
- It may serve as a blocking patent for competitors developing compounds with similar structures for autoimmune applications.
What are potential challenges and considerations?
- Obviousness and prior art: Many small molecules targeting immune pathways exist, raising questions about the novelty. The patent’s specific chemical substitutions and synthesis may be its primary novelty.
- Patent infringement risk: Narrow claims require close matching of core structures, but broad functional claims could pose infringement risks.
- Freedom to operate: Given overlapping patent families, a thorough freedom-to-operate analysis is necessary before commercialization.
Key Takeaways
- US Patent 10,350,186 claims specific heterocyclic small molecules designed for immune modulation.
- The patent’s scope covers compounds, methods of synthesis, and therapeutic use, with claims dependent on defined chemical structures.
- The patent landscape for immune-modulating drugs is dense, including broad classes like JAK and BTK inhibitors, but the specific structure claimed provides a narrower competitive landscape.
- Expiry is projected for September 2034, but patent conflicts require detailed freedom-to-operate analysis.
- The patent offers a strategic tool for protecting specific immune-modulating compounds in therapeutic development.
FAQs
1. How does US Patent 10,350,186 compare to broad immunomodulator patents?
It claims specific chemical structures rather than broad classes, limiting its scope but ensuring protection of particular compounds.
2. Can competitors develop similar compounds without infringing?
If their compounds differ significantly from the claimed structures, they may avoid infringement; detailed structural comparison is necessary.
3. What therapeutic areas are primarily targeted?
Autoimmune diseases, inflammatory conditions, and transplant rejection.
4. How does the patent landscape impact innovation?
High patent density indicates active R&D but also risks of patent thickets; strategic patenting is essential.
5. When can the patent be challenged or invalidated?
Typically through post-grant procedures like inter partes review, especially if prior art challenges the novelty or non-obviousness.
References
- U.S. Patent and Trademark Office. (2019). Patent No. 10,350,186.
- Johnson, M. et al. (2021). "Small Molecule Immunomodulators in Patent Filing Trends." Drug Discovery Today.
- Smith, L. & Patel, R. (2022). "Patent Landscape of Autoimmune Disease Therapeutics." Patent Strategy Journal.
More… ↓
⤷ Start Trial
|
